Navigation Links
Covance Receives Highest Level of Phase I Accreditation
Date:7/30/2009

PRINCETON, N.J., July 30 /PRNewswire/ -- Covance Inc. today announced that it has received standard and supplementary accreditation for the conduct of clinical pharmacology in Europe by the Medicines and Healthcare products Regulatory Agency (MHRA). This voluntary accreditation process provides clinical trial volunteers and sponsors with confidence that research facilities and studies meet the industry's highest safety standards.

This accreditation was awarded to Covance's clinical research unit in Leeds, United Kingdom, where the company conducts first-in-human studies, including trials requiring a review of risk factors by the Expert Advisory Group.

"Covance delivers the highest level of data quality and patient safety for first-in-human trials, which is confirmed by the MHRA accreditation," said Rob Aspbury, M.D., managing director, clinical research services, Covance. "As an industry leader in clinical pharmacology, Covance provides superior experience and expertise in study design and conduct to support today's increasingly complex first-in-human trials."

MHRA accreditation was introduced to ensure the highest level of patient safety for early clinical development by providing more information about trial facilities. The process includes formal routine inspections that provide additional scope and depth to existing procedures for good clinical practice inspections.

Covance's clinical pharmacology expertise includes full-time physicians, clinical pharmacologists, registered pharmacists and more than 30 Advanced Life Support (ALS) trained nurses. The industry leader in the conduct of clinical pharmacology studies, Covance offers more than 500 beds across nine Phase I clinics located in the United States, United Kingdom, and Switzerland.

About Covance
'/>"/>

SOURCE Covance Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies
2. Worlds First Cardiac Adult Stem Cell Patient Receives Infusion
3. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
4. Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks
5. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
6. USC Keck School of Medicines Dr. Alan Epstein Receives Prestigious National Cancer Institute RAID Award for Breakthrough IL-2 Molecule Therapeutic
7. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
8. SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
9. Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)
10. Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System
11. DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013  IsoRay, Inc. (AMEX: ... that it has entered into an exclusive international distribution ... complete product line in Greece . ... seed brachytherapy and medical radioisotope applications for brain cancer, ... gynecologic ("gyn") cancer. IASIS Medical is ...
(Date:5/21/2013)... 2013 Hurel Corporation ("Hurel"), a world-leading provider ... platforms, today announced the appointment of James ... Board of Directors. Dr. MacDonald is the former Executive ... Institute ("SPRI"), which was the pharmaceutical development arm of ... Co. in 2009. Over a career that ...
(Date:5/21/2013)... BioElectronics Corp. (PINKSHEETS: BIEL), the maker ... that CEO, Andrew J. Whelan ... Advisory Committee, Orthopedic and Rehabilitation Panel compelling arguments ... counter sales. "It,s been 37 years ... schema," Whelan said.  "While the old classification of ...
Breaking Medicine Technology:IsoRay Announces A New International Distributor For Greece 2IsoRay Announces A New International Distributor For Greece 3Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors 2BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3
... NEW HAVEN, Conn., Aug. 5 Rib-X ... company focused on the,discovery and development of ... announced today that company,representatives are giving three ... Research Conference on Medicinal Chemistry, August 3-8, ...
... Aug. 5 Nexgen Spine, a leading,developer of ... disc disease, announced today that it has received ... Disc in the European,Union., "We are delighted ... mark approval," said Alastair Clemow, Ph.D., President and ...
Cached Medicine Technology:Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences 2Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences 3Nexgen Spine Receives CE Mark Approval for the Physio-L(R) Artificial Disc 2
(Date:5/21/2013)... glioblastoma brain tumor cells that uses a modified poliovirus ... establish the proper dose level, researchers at Duke Cancer ... tested in an ongoing phase 1 study, capitalizes on ... receptors that work like magnets drawing the poliovirus, which ... investigational therapy, known as PVSRIPO, uses an engineered form ...
(Date:5/21/2013)... 2013 STAR (Sensory Therapies And ... with sensory challenges and the Sensory Processing Disorder ... and advocacy of Sensory Processing Disorder present Stumbling Blocks ... Improve Quality of Life, a two-hour lecture presented by ... , Learn a method that can aid in ...
(Date:5/21/2013)... As the summer season kicks off, ... camp or beginning practice for summer or fall sports. ... or sporting activities can begin. , To help parents during ... youth sports or camp physicals at just $29. ... review a child’s medical history, perform a physical exam and ...
(Date:5/21/2013)... Diehard soccer fans will definitely want to ... the game between Manchester City and Chelsea FC ... These two teams are highly decorated in the English Premiere ... to the Busch Stadium, home of the St. Louis Cardinals, ... time that a professional sporting event and non-baseball game will ...
(Date:5/21/2013)... 21 (HealthDay News) -- Urban elementary school children ... sleep problems and suffer academically, new research indicates. ... seven to nine, we found that compromised lung ... impaired academic performance," said study author Daphne ... behavior at Brown University,s Alpert Medical School in ...
Breaking Medicine News(10 mins):Health News:Poliovirus vaccine trial shows early promise for recurrent glioblastoma 2Health News:STAR Center and SPD Foundation Present a Lecture on Teens and Adults with Sensory Processing Disorder 2Health News:STAR Center and SPD Foundation Present a Lecture on Teens and Adults with Sensory Processing Disorder 3Health News:MedSpring Offers Affordable Youth Physicals for $29 2Health News:Manchester City vs. Chelsea FC Tickets: Cheap Concert Tickets has Slashed Prices on Manchester City vs. Chelsea FC Tickets at Busch Stadium in St. Louis, MO 2Health News:Sleepless Nights May Hurt School Performance of Kids With Asthma 2
... Christian Davis Furman, M.D., M.S.P.H., vice chair for ... Medicine at the University of Louisville, has been selected ... Innovation Advisors Program. She is the only Kentuckian among ... of Columbia selected to participate. The ...
... New York (CCNY) whose research unites the divergent fields ... honored this month for his pioneering work in biomedical ... photonics. SPIE will present Dr. Robert Alfano, CUNY ... the first annual Britton Chance Biomedical Optics Award January ...
... FRIDAY, Jan. 6 (HealthDay News) -- If you,re 50 or ... screened for colorectal cancer, the American Society for Gastrointestinal Endoscopy ... cancers because most cases arise from precancerous growths in the ... exam and removed before they turn into cancer. Recent ...
... Fla. (Jan. 6, 2012) A malignancy-risk gene signature ... predictive and prognostic value for patients with early stage ... researchers at Moffitt Cancer Center in Tampa, Fla., who ... the Journal of the National Cancer Institute . ...
... Linagliptin (trade name: Trajenta) has been approved since August ... adults with type 2 diabetes mellitus whose elevated blood ... It is an option for patients who do not ... the drug metformin. Moreover, linagliptin can be added if ...
... Reinberg HealthDay Reporter , THURSDAY, Jan. 5 ... U.S. advisory panel,s recommendation to lower the threshold for ... once common in gasoline and house paint, can permanently ... Committee on Childhood Lead Poisoning Prevention voted to recommend ...
Cached Medicine News:Health News:UofL geriatrician selected for new federal Innovation Advisors Program 2Health News:CCNY's Robert Alfano wins first biomedical optics award 2Health News:CCNY's Robert Alfano wins first biomedical optics award 3Health News:Resolve to Take Colon Cancer Test, Experts Say 2Health News:Researchers find malignancy-risk gene signature for early-stage non-small cell lung cancer 2Health News:Added benefit of linagliptin is not proven 2Health News:Experts Endorse Lower Lead-Poisoning Threshold 2Health News:Experts Endorse Lower Lead-Poisoning Threshold 3
... The Vitros 950 provides power ... needs of high volume testing ... up to 900 results per ... store and perform the full ...
... Monitoring Market in 1981 with the introduction ... this system uses technology known as FPIA ... concentration in a patient. Therapeutic Drugs, used ... exhibit a narrow therapeutic range requiring close ...
AxSYM Plus provides cutting-edge ergonomics and smart new features that mean increased ease-of-use and enhanced reliability. Also, advanced software means less operator intervention and high-integrit...
Architect i2000SR provides high productivity. Seamless integration optimize performance....
Medicine Products: